Serine Metabolism: Some Tumors Take the Road Less Traveled  by DeBerardinis, Ralph J.
Cell Metabolism
PreviewsSerine Metabolism: Some Tumors
Take the Road Less TraveledRalph J. DeBerardinis1,2,*
1Department of Pediatrics
2McDermott Center for Human Growth and Development
University of Texas Southwestern Medical Center, Dallas TX 75390-9063, USA
*Correspondence: ralph.deberardinis@utsouthwestern.edu
DOI 10.1016/j.cmet.2011.08.004
Cancer cells display a reprogramming of metabolism that facilitates growth but addicts them to key enzyme
activities. Two studies in Nature and Nature Genetics find that the gene encoding the serine biosynthetic
enzyme phosphoglycerate dehydrogenase (PHGDH) is amplified in a subset of cancers and contributes to
tumor cell growth.Cancer cells possess metabolic proper-
ties that distinguish them from nonmalig-
nant cells. Of enduring interest is their
propensity to take up glucose in large
amounts and convert it to lactic acid:
the so-called Warburg effect (Koppenol
et al., 2011). The causes and benefits of
this phenomenon have been the focus of
study and speculation for many years
(Vander Heiden et al., 2009). Since the
mid 1990s, which brought a resurgence
of interest in cancer metabolism, a large
body of work has demonstrated that en-
hanced glycolysis is a common conse-
quence of the perturbed signal trans-
duction that accompanies transforming
mutations: that is, mutations in tumor
suppressors and oncogenes lead, and
metabolism follows. These mechanistic
links with well-established driver muta-
tions support the consensus that en-
hanced glycolysis is both a hallmark of
malignant transformation and a potential
therapeutic target (Hanahan and Wein-
berg, 2011).
But recent evidence implies that meta-
bolic reprogramming can also occur as
the result of genomic modifications of
metabolic enzymes and that these alter-
ations independently contribute to tumor-
igenesis. Two new studies published in
Nature Genetics and Nature (Locasale
et al., 2011; Possemato et al., 2011) report
that the gene encoding phosphoglycerate
dehydrogenase (PHGDH) is amplified in
a significant subset of human tumors.
The two studies converged on PHGDH
from different starting points. Possemato
et al. identified it from a loss-of-function
RNA-interference screen for metabolic
genes required for tumorigenesis in anorthotopic model of breast cancer. Loca-
sale et al. studied the fate of glucose-
derived carbon in cancer cell lines and
observed significant flux into metabolites
downstream of PHGDH. Both studies
then mined databases of copy number
alterations in cancer to determine that
the PHGDH gene on chromosome 1p12
is amplified in 6% of breast cancers
and 40% of melanomas. Subsequent
experiments showed that a much larger
fraction of tumors had elevated PHGDH
protein levels, including 70% of estrogen
receptor-negative breast tumors. High
PHGDH expression with or without
genomic amplification was associated
with dependence on the enzyme for cell
growth, suggesting that subsets of tumor
cells are addicted to flux through this
metabolic pathway.
PHGDH is a fascinating and at first
glance surprising metabolic target in
cancer. It catalyzes entry into what
amounts to ametabolic side street, divert-
ing flux away from the ‘‘superhighway’’ of
tumor cell glycolysis (Figure 1). Thus, it
would appear to reduce energy formation
from glucose. But the PHGDH pathway
also provides many advantages for grow-
ing cells. First, de novo synthesis of serine
and glycine, precursors for a variety of
biosynthetic pathways, requires the
removal of 3-phosphoglycerate from
glycolysis via PHGDH. Second, conver-
sion of serine to glycine by serine hydrox-
ymethyltransferase (SHMT) is a major
source of methyl groups for the one-
carbon pools required for biosynthesis
and DNA methylation. Furthermore, there
were a few previous hints that serine/
glycine biosynthesis might be importantCell Metabolism 14, Sin tumorigenesis. In breast tumors, ex-
pression of several enzymes in the
pathway, including PHGDH itself, corre-
lated with metastasis in mice and poor
clinical outcomes in humans (Pollari et al.,
2011). Also, two isoforms of SHMT are
transcriptional targets of the oncogene
c-Myc, and SHMT overexpression stimu-
lated proliferation in c-Myc-deficient cells
(Nikiforov et al., 2002).
Yet both serine and glycine are abun-
dant in the plasma, so it was not immedi-
ately clear what could be gained by upre-
gulating their de novo synthesis at the
expense of glycolysis. Possemato et al.
made the counterintuitive observation
that silencing PHGDH expression did not
deplete intracellular serine, suggesting
that some other output of the pathway
must contribute to cell growth. Another
metabolite generated during serine bio-
synthesis is a-ketoglutarate (aKG), pro-
duced at the transamination step that
converts 3-phosphohydroxypyruvate to
3-phosphoserine (Figure 1). aKG is also
the entry point through which glutamine
supplies carbon to the tricarboxylic acid
(TCA) cycle during cell growth, enabling
the production of many essential biosyn-
thetic precursors. Surprisingly, as much
as half of all glutamine-derived aKG in
PHGDH-overexpressing cells was gener-
ated via the PHGDH pathway. The com-
pelling implication is that PHGDH could
serve as a metabolic gatekeeper both
for macromolecular biosynthesis down-
stream of glutamine metabolism (i.e., cell
growth) and serine-dependent DNA syn-
thesis (i.e., cell proliferation).
Is PHGDH a feasible therapeutic target
in breast cancer, melanoma, or othereptember 7, 2011 ª2011 Elsevier Inc. 285
Figure 1. Role of PHGDH in Tumor Cell Metabolism
Many tumors have enhanced expression of the metabolic enzyme phosphoglycerate (PHGDH), in some
cases because the gene encoding this enzyme is amplified on chromosome 1p12. PHGDH diverts flux
away from glycolysis by oxidizing 3-phosphoglycerate (3-PG) to 3-phospho-hydroxypyruvate (3-POHPyr).
Subsequent metabolism of this 3-carbon intermediate feeds into the serine and glycine pools, providing
numerous precursor molecules and other substrates required for cell growth and proliferation. Ac-CoA,
acetyl-CoA; aKG, a-ketoglutarate; DHAP, dihydroxyacetone phosphate; GA3P, glyceraldehyde-3-phos-
phate; NH4
+, ammonium ion; N5N10-MTHF, N5,N10-methylene tetrahydrofolate; OAA, oxaloacetate; PEP,
phosphoenolpyruvate; PSAT1, phosphoserine aminotransferase-1; SAM, S-adenosylmethionine; SHMT,
serine hydroxymethyltransferase; THF, tetrahydrofolate.
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lencing PHGDH in established breast
tumors reduced their growth in mice,
a promising finding. However, as is often
the case for core metabolic enzymes,
global PHGDH deficiency is associated
with severe neurologic dysfunction in
children (Jaeken et al., 1996). But perhaps
using agents with poor access to the
central nervous system would be ade-
quately tolerated in cancer patients, or
perhaps the exquisite dependence of
selected tumors on PHGDH could provide
a safe therapeutic window.
PHGDH joins a growing list of putative
metabolic oncogenes and tumor sup-
pressors whose alteration in the genome
reorchestrates the metabolic roadmap286 Cell Metabolism 14, September 7, 2011 ªand may influence the development of
malignant properties (Frezza et al., 2011).
In a few cases, the relationship between
enzyme mutation and oncogenesis is
well established. Some familial cancer
syndromes are caused by mutations in
fumarate hydratase (FH) or in the succi-
nate dehydrogenase (SDH) complex. In
affected individuals, a loss-of-function
mutation is inherited on one allele, and
the other allele is deleted or otherwise
mutated in the tumor, establishing these
genes as true tumor suppressors. More
recently, mutations in two isoforms of
isocitrate dehydrogenase (IDH1 and
IDH2) were identified through genome se-
quencing in gliomas and acute myeloid
leukemia. Somatic acquisition of specific2011 Elsevier Inc.active-site mutations in one allele of either
enzyme conveys a gain-of-function enzy-
matic activity, producing a metabolite,
2-hydroxyglutaric acid, with suspected
effects on cell signaling, epigenetics, and
transformation (Figueroa et al., 2010).
Thus, mutant forms of IDH1 and IDH2
may function as bona fide oncogenes.
Can the same be said of PHGDH? Loca-
sale et al. found that PHGDH overexpres-
sion stimulates anchorage independence
and disturbs polarity in mammary epithe-
lial cells, features strongly correlated with
malignancy. Precisely how mutations in
any of these enzymes contribute to trans-
formation and tumorigenesis is an ex-
tremely active area of research. Surely
these genetically determined ‘‘metabolic
outliers’’ hold important clues about
the biological basis of malignancy and
the specific metabolic features selected
during tumorigenesis.REFERENCES
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